These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 39395006)
21. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice. Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923 [TBL] [Abstract][Full Text] [Related]
22. Tuning complement activation and pathway through controlled molecular architecture of dextran chains in nanoparticle corona. Coty JB; Eleamen Oliveira E; Vauthier C Int J Pharm; 2017 Nov; 532(2):769-778. PubMed ID: 28450168 [TBL] [Abstract][Full Text] [Related]
23. Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture. Yu M; Huang S; Yu KJ; Clyne AM Int J Mol Sci; 2012; 13(5):5554-5570. PubMed ID: 22754315 [TBL] [Abstract][Full Text] [Related]
24. Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines. Gabizon A; Szebeni J ACS Nano; 2020 Jul; 14(7):7682-7688. PubMed ID: 32643376 [TBL] [Abstract][Full Text] [Related]
25. High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. Wang G; Inturi S; Serkova NJ; Merkulov S; McCrae K; Russek SE; Banda NK; Simberg D ACS Nano; 2014 Dec; 8(12):12437-49. PubMed ID: 25419856 [TBL] [Abstract][Full Text] [Related]
26. Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals. Chen BM; Su YC; Chang CJ; Burnouf PA; Chuang KH; Chen CH; Cheng TL; Chen YT; Wu JY; Roffler SR Anal Chem; 2016 Nov; 88(21):10661-10666. PubMed ID: 27726379 [TBL] [Abstract][Full Text] [Related]
27. Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D Front Immunol; 2016; 7():418. PubMed ID: 27777575 [TBL] [Abstract][Full Text] [Related]
28. Engineering PEGylated Polyester Nanoparticles to Reduce Complement-Mediated Infusion Reaction. Maisha N; Naik N; Okesola M; Coombs T; Zilberberg R; Pandala N; Lavik E Bioconjug Chem; 2021 Oct; 32(10):2154-2166. PubMed ID: 34499487 [TBL] [Abstract][Full Text] [Related]
29. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689 [TBL] [Abstract][Full Text] [Related]
30. PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies. Bavli Y; Chen BM; Roffler SR; Dobrovolskaia MA; Elnekave E; Ash S; Barenholz Y; Turjeman K Molecules; 2020 Jan; 25(3):. PubMed ID: 32012928 [TBL] [Abstract][Full Text] [Related]
31. Characterization of factors influencing on-chip complement activation to optimize parallel measurement of antibody and complement proteins on antigen microarrays. Papp K; Végh P; Hóbor R; Erdei A; Prechl J J Immunol Methods; 2012 Jan; 375(1-2):75-83. PubMed ID: 22000977 [TBL] [Abstract][Full Text] [Related]
33. Opsonization of bacteroides by the alternative complement pathway reconstructed from isolated plasma proteins. Bjornson AB; Magnafichi PI; Schreiber RD; Bjornson HS J Exp Med; 1987 Mar; 165(3):777-98. PubMed ID: 3819646 [TBL] [Abstract][Full Text] [Related]
34. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Frid MG; McKeon BA; Thurman JM; Maron BA; Li M; Zhang H; Kumar S; Sullivan T; Laskowsky J; Fini MA; Hu S; Tuder RM; Gandjeva A; Wilkins MR; Rhodes CJ; Ghataorhe P; Leopold JA; Wang RS; Holers VM; Stenmark KR Am J Respir Crit Care Med; 2020 Jan; 201(2):224-239. PubMed ID: 31545648 [No Abstract] [Full Text] [Related]
35. Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles. Wang Z; Hood ED; Nong J; Ding J; Marcos-Contreras OA; Glassman PM; Rubey KM; Zaleski M; Espy CL; Gullipali D; Miwa T; Muzykantov VR; Song WC; Myerson JW; Brenner JS Adv Mater; 2022 Feb; 34(8):e2107070. PubMed ID: 34910334 [TBL] [Abstract][Full Text] [Related]
36. Complement Inhibitors Block Complement C3 Opsonization and Improve Targeting Selectivity of Nanoparticles in Blood. Gaikwad H; Li Y; Gifford G; Groman E; Banda NK; Saba L; Scheinman R; Wang G; Simberg D Bioconjug Chem; 2020 Jul; 31(7):1844-1856. PubMed ID: 32598839 [TBL] [Abstract][Full Text] [Related]
37. Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory. Lin W; Li A; Qiu L; Huang H; Cui P; Wang J Mol Pharm; 2024 Jun; 21(6):2970-2980. PubMed ID: 38742943 [TBL] [Abstract][Full Text] [Related]
38. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis. Holzer TJ; Edwards KM; Gewurz H; Mold C J Immunol; 1984 Sep; 133(3):1424-30. PubMed ID: 6747291 [TBL] [Abstract][Full Text] [Related]
39. Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation. Mostafa M; Elsadek NE; Emam SE; Ando H; Shimizu T; Abdelkader H; Ishima Y; Aly UF; Sarhan HA; Ishida T Biol Pharm Bull; 2022; 45(1):129-135. PubMed ID: 34980774 [TBL] [Abstract][Full Text] [Related]
40. Patient-Specific Nanoparticle Targeting in Human Leukemia Blood. Ju Y; Li S; Tan AEQ; Pilkington EH; Brannon PT; Plebanski M; Cui J; Caruso F; Thurecht KJ; Tam C; Kent SJ ACS Nano; 2024 Oct; 18(42):29021-29035. PubMed ID: 39380440 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]